Business

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or ...

articleIgc Pharma, Inc.May 15, 20263/company/igc-pharma-inc/news/igc-pharma-to-present-tau-pet-biomarker-research-at-2026-global-tau-conference
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

About this update from Igc Pharma, Inc.

[{"type":"text","content":"Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development.","length":159,"tagName":"p"},{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C., and online.","length":417,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/e71d1130dfca6fa7cd6d48978ef188b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6aSHjMYFEDO0oFlgkc93zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2OA--/https://media.zenfs.com/en/accesswire.ca/e71d1130dfca6fa7cd6d48978ef188b1","width":960,"height":568},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/be1l7kjshtdmzRYzXgDy8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM3OQ--/https://media.zenfs.com/en/accesswire.ca/e71d1130dfca6fa7cd6d48978ef188b1","width":640,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CYvnKESiHR19Zqe1F4Zrng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIw/https://media.zenfs.com/en/accesswire.ca/e71d1130dfca6fa7cd6d48978ef188b1","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/d8eb3517-f4c2-4ee4-bec0-a6a281e1591c/igc-pharma-inc-2026.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The poster presentation, titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's Disease Progression in Amyloid-Positive APOE4 Carriers," evaluates whether Shannon entropy can serve as a quantitative measure of spatial heterogeneity in tau pathology, a key feature of Alzheimer's disease progression.","length":336,"tagName":"p"},{"type":"text","content":"The analysis utilized F-AV-1451 Tau-PET imaging data from 931 participants and 1,570 scans obtained through the Alzheimer's Disease Neuroimaging Initiative (ADNI). The team assessed whether tau distrib...

More updates from Igc Pharma, Inc.

Alzheimer's diseaseShannon EntropyGlobal Tau ConferenceAlzheimer's researchspatial heterogeneitydisease progressionThe Companyclinical studiestau proteins